• Ellie Tsiamis, Jeremy Millar, Siddhartha Baxi, Martin Borg, Paolo De Ieso, Hany Elsaleh, Farshad Foroudi, Braden Higgs, Tanya Holt, Jarad Martin, Kim Moretti, David Pryor, Marketa Skala, and Sue Evans.
• Department of Epidemiology & Preventative Medicine, Monash University, Melbourne, Australia. Electronic address: ellie.tsiamis@monash.edu.
• Radiother Oncol. 2018 Aug 1; 128 (2): 308-314.

Background And PurposeQuality indicators (QIs) have been developed for many aspects of prostate cancer care, but are under-developed with regard to radiotherapy treatment. We aimed to develop a valid, relevant and feasible set of core QIs to measure quality of radiotherapy care in men with prostate cancer.Materials And MethodsWe used a RAND-modified Delphi process to select QIs that were regarded as both important and feasible measures of quality radiotherapy care. This involved two phases: (1) a literature review to identify a list of proposed QIs; and (2) a QI selection process by an expert panel (n = 12) conducted in a series of three rounds: two online questionnaires' and one face-to-face meeting. The RAND criterion identified variation in ratings and determined the level of agreement after each round of voting.ResultsA total of 144 candidate QIs, which included measures from pre-treatment to post-treatment and survivorship care were identified. After three rounds of voting, the panel approved a comprehensive set of 17 QIs, with most assessing a process of care (n = 16, 94.1%) and the remaining assessing a health outcome.ConclusionThis study developed a core set of 17 QIs which will be used to report from the Prostate Cancer Outcomes Registry-Australia & New Zealand, to monitor the quality of radiotherapy care prostate cancer patients receive.Copyright © 2018 Elsevier B.V. All rights reserved.

15 keywords...

hide…